CPC in Adult Refractory Glaucoma

January 9, 2022 updated by: Mina Abdelmalek Besada, Sohag University

Evaluation of Diode Laser Cyclophotocoagulation in Adult Refractory Glaucoma

The purpose of this study is to assess the relative effectiveness and safety of diode laser cyclophotocoagulation procedure to reduce IOP and relieve pain in adult patients with refractory glaucoma.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

A hospital -based, prospective interventional non comparative case series study.This study will be conducted on patients with refractory glaucoma whose ages are 18 years and older.They will be subjected to Transscleral Diode Laser Cyclophotocoagulation.

Postoperative evaluation will be scheduled for the first day postoperative, then 1 week later and then at 1st, 3rd, month postoperative.

Study Type

Interventional

Enrollment (Anticipated)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Ismail M Abdellatif, Professor
  • Phone Number: 01223629352

Study Locations

  • Egypt
      • Sohag, Egypt
        • Recruiting
        • Sohag University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients with refractory glaucoma aging 18 years and older.
    2. Both sexes are included.
    3. Patients Capable of giving informed consent.
    4. Pseudophkic glaucoma.
    5. Aphakic glaucoma.
    6. Silicon oil induced glaucoma.
    7. Neovascular glaucoma.
    8. Inflammatory glaucoma.

Exclusion Criteria:

  1. Patients <18 years of age.
  2. Patients controlled on regular antiglaucomatous therapy.
  3. Patients who cannot do regular follow up visits.
  4. Diffuse scleral staphyloma at the site of CPC.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Refractory glaucoma
Procedure: Diode Laser Cyclophotocoagulation
A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in intraocular pressure
Time Frame: First day postoperative and 1 week
IOP measuring using Goldmann applanation tonometer.
First day postoperative and 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Anticipated)

April 1, 2022

Study Completion (Anticipated)

April 1, 2022

Study Registration Dates

First Submitted

May 30, 2021

First Submitted That Met QC Criteria

June 4, 2021

First Posted (Actual)

June 10, 2021

Study Record Updates

Last Update Posted (Actual)

January 11, 2022

Last Update Submitted That Met QC Criteria

January 9, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-05-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Refractory Glaucoma

Clinical Trials on Diode Laser Cyclophotocoagulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe